« Back
Home /
ERα degrader 4

ERα degrader 4

Item no.	HY-144306-100mg
Manufacturer	MedChem Express
Amount	100 mg
Quantity options	100 mg 1 ea
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Citations	[1]Liang JJ, et al. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment. Eur J Med Chem. 2022;229:114081.
Smiles	[H][C@]12C[C@]3(CC[C@]([C@H](/C=C\C=C/C(OCCOCCOCCOC(CC45CC6CC(C5)CC(C6)C4)=O)=O)C)([C@@]3(C/C=C([C@@]1(C(C=C2C)=O)[H])/C=O)[H])[H])C
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Estrogen Receptor/ERR
Shipping Temperature	Room temperature
Molecular Weight	690.91
Product Description	ERα degrader 4 is an excellent and selective estrogen receptor α (ERα) degrader (IC50 of 0.31, 0.41 and 0.48 μM in MDA-MB-231, MCF-7 and MCF-7/ADR cells, respectively). ERα degrader 4 has potent inhibitory activity against MCF-7 cell lines. ERα degrader 4 is a potential SERDs candidate for the research of breast cancer[1].
Manufacturer - Research Area	Cancer
Solubility	10 mM in DMSO
Manufacturer - Pathway	Apoptosis; Vitamin D Related/Nuclear Receptor
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question